KT
Kestrel Therapeutics Inc.
SEC filingBiotechnology · Boston, MA
Amount raised$5Msold at filing
Total offering$10M$5M still open
Investors in the raise6count reported to the SEC
FiledAug 12, 2025first sale Jul 28, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Nicholas G. SaccomanoDirector
Denis G. PatrickDirector
Barbara G. SosnowskiDirector
Omar G. KhalilDirector
Andrew G. PhillipsDirector
Frank G. HaluskaExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.